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Structure of CYP2D6Cytochromes are proteins that catalyze electron transfer reactions of many metabolic pathways. They are
involved in drug metabolism and thus determines the therapeutic safety and efficacy of drugs in patients.
Cytochrome P450 in mitochondria accounts for 90% of the oxidative metabolism of clinically used drugs
during phase 1 reaction. CYP2D6 is a major gene member of this superfamily as it carries out metabolism
of 25% of drugs currently available in the market. Contrary to the concept of specificity of enzyme action
these can metabolize substrates of different chemistry. Since its discovery, many have intensively studied
this unique hemoprotein and contributed to the elucidation of its molecular properties and physiological
functions and also the structure-activity relationships of its substrates and inhibitors. Its activity ranges
considerably within a population due to genetic polymorphisms which lead to varied responses to drug
intake. Studying such polymorphisms which cause a significant impact in the management of patients
and helps to achieve the final target of personalizing medicine. This review briefs about history, structure,
and function, molecular genetics, substrates, regulators and inhibitors of CYP2D6 and its clinical
pharmacogenomics.
 2017 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
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The ability to metabolize drugs is a natural process which
involves the same enzymatic pathways and transport systems that
are used for normal metabolism of dietary constituents. They are
called xenobiotic metabolizing enzymes. Drugs which are lipophi-
lic need to be changed into water soluble compounds for excretion
from the body, if not leads to accumulation and toxicity. This pro-
cess happens via chemical reactions which involve two phases;phase 1 and 2. The enzymes for these are found in most tissues
in the body with the highest levels located in the gastrointestinal
tract (liver, small and large intestines). Other sites are kidney,
breast, brain and lungs. Intracellular membranes and cytosol of
cells contain these enzymes. These enzymes are pigments (cyto-
chromes) as they contain haem and are found in all organisms in
the prokaryotic and eukaryotic world from animals, plants, fungi,
protists, bacteria and archaea to virus. There are different types
of cytochromes of which cytochrome P450 is unique in its drug
metabolizing function. Genetic variation in their genes leads to a
varied response to drug intake. Three families of CYPs (Cytochrome
P450), namely CYP1s, CYP2s, and CYP3s are the main ones
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ical drugs [1]. CYP2D6 is one of the most widely investigated CYPs.
25% of currently marketed drugs are substrates for CYP2D6 though
it only constitutes 2–4% of the total hepatic CYPs [2]. Its substrate
includes antidepressants, antipsychotics, analgesics, antitussives,
b-blocking agents, antiarrhythmics, and antiemetics and thus its
different drug metabolism affects the clinical outcome.2. History of cytochrome P450
In 1885 Dr.Mac Munn discovered two new pigments in animals,
which he named as myohaemetin and histohaemetin and pub-
lished it in the Proceedings of Physiological Society, Royal College
of London. He mentioned them as respiratory pigments as they
undergo oxidation and reduction in solid organs without getting
destroyed. Later in 1929 David Keilin an entomologist while study-
ing the life cycle of horse bot fly noticed red pigments in its larvae
that feed on a horse. He got interested about animal pigments that
led further research in this field. In his article about respiratory
enzymes, he named the pigments as cytochromes and explained
the different types of cytochromes based on their position in the
absorption band as cytochromes a (605 nm), b (565 nm) and c
(550 nm) [3]. Klingenberg in 1955 discovered a new carbon
monoxide binding pigment in rat liver microsomes at Johnsonn
Research Foundation, Philadelphia [4]. He reduced microsomal
suspension compounds by adding DPNH (DiPhosphopyridine
Nucleotide) and studied its spectra using wavelength-scanning
recording spectrophotometer and observed a prominent optical
absorption peak at 450 nm. This absorption spike was different
from other haem proteins which usually show CO (Carbon Monox-
ide) difference spectra between 500 and 650 nm. Aerated micro-
some suspension when bubbled with CO didn’t show any peak
indicating that P450 is a reducible pigment, and only the reducible
form could bind CO. Omura et al. repeated Klingenberg’s experi-
ments using rabbit liver microsomes and found similar results in
its absorption spectra [5]. He named the pigment as P450 where
P stands for ‘‘pigment”. When treated with detergents the absorp-
tion peak at 450 disappeared, and a parallel peak appeared at
420 nm which was due to the formation of a more solubilised
P420. Spectral data of P420 helped in finding the molar attenuation
coefficient of carbon monoxide difference spectrum of P450. Thus
they could calculate the amount of P450 in the microsomes, and
the total content of protoheme was accountable by the sum of
cytochrome b5 (a ubiquitous electron transport hemoprotein)
and P450. This 450 peak is shared only by four classes of haem pro-
teins, others being nitric oxide synthases, chloroperoxidases, and
protein H450. Thus they were grouped under enzymes which help
in oxidation and reduction.3. Human CYP2D6; structure and function
The purification of the CYP enzymes was done with chemical
stabilization techniques developed by Ichikawa et al. and Coon
et al. in 1969 [6]. The primary structure of the protein (high-
resolution crystal structure) was elucidated in Pseudomonas
putida in 1982 [7]. CYPs are embedded in the phospholipid bilayer
of endoplasmic reticulum in the cytosolic surface. Enzyme called
NADPH-CYP450 oxidoreductase seen close to CYP transfers elec-
trons to all forms of cytochromes. Each CYP contains one molecule
of iron-protoporphyrin IX which binds with oxygen and a non-
covalently bound polypeptide chain. The detailed study of the
structure revealed two conformations; open and closed. These
symmetries are important as switching between them is needed
for substrate access to the active site. Most of the P450s share
the form change of closed to the partly open configuration. Theactive site of drug metabolizing cytochromes adapts to several sub-
strates which explain the multi-drug metabolizing properties of
several cytochromes. Active site cavity of CYP2D6 is bordered by
the haem and lined by many amino acid residues and is of 540
A3 (Angstrom) size which can accommodate a number of sub-
strates with distinct structures [8]. The entry to the active site is
obscured while in closed form, but the access channel undergoes
a significant increase in thermal motion which shows that fluctua-
tions do occur to allow a substrate to reach the active site. Four
amino acids are conserved in the 57 functional CYPs; Glu-242 (Glu-
tamate), Arg-245 (Arginine), Phe-310(Phenylalanine) and Cys-316
(Cysteine) of which phenylalanine and cysteine are seen near heme
binding region.
It was aware that carbon monoxide inhibited the metabolism of
steroids in experimental studies. Detailed study of this inhibition
using photochemical action spectrum method found that cyto-
chrome P450 is also present in mitochondria and is involved in
the synthesis of steroids helping in hydroxylation of 17a hydrox-
yprogesterone. Carbon monoxide competes with molecular oxygen
for the active site of P450 as it acts as the oxygenase for the
hydroxylation step. Estabrook and Omura worked together to find
the actual mechanism of reactions involving P450 and first eluci-
dated P450 enzyme electron transfer in 1966 [9]. The electron
has to flow through NADPH-linked soluble flavoprotein and a
non-haem iron protein to reduce P450 and which in turn reacts
with oxygen and substrate in which one atom of oxygen is used
to reoxidize itself and other to hydroxylate the substrate. This oxi-
dation process consumes more oxygen compared to substrate
metabolized in the reaction resulting in the generation of free rad-
icals that become water by the action of superoxide dismutase.
CYPs are involved in the phase 1 reactions of drug metabolism like
aromatic hydroxylation, N-oxidation, N-dealkylation, O-
dealkylation, S-oxidation, deamination, and dehalogenation. CYPs
also catalyze many unusual reactions such as one-and-two-
electron reductions, one-electron oxidation, oxidation cleavage of
carboxylic acid esters, desaturation, deformylation of aldehydes,
ring formation, ipso mechanisms of aryl dehalogenation and O-
and N- dearylation, rearrangements of oxidized eicosanoids, aldox-
ime dehydration and hydrolysis of phosphatidyl choline. The esti-
mated half-life of human CYP2D6 is 46.6 to 51 h [10]. Any factors
which change the stability and degradation of human CYPs will
change their half-life and thus modify the drug metabolism.4. Molecular genetics of CYPs
Modern P450s originated from an ancestral gene in prokaryotes
that existed approximately 3.5 billion years back, before the advent
of eukaryotes and the existence of oxygen-rich atmosphere and
they functioned as nitroreductases and endoperoxide isomerases.
When earth’s atmosphere started to accumulate oxygen, then CYPs
protected early life forms from oxygen toxicity. This evolution hap-
pens by the process of repeated rounds of expansion of CYPs by
gene duplication, exon shuffling, expression of overlapping genes,
programmed frame shifting, alternative splicing, RNA editing and
gene sharing. Around 1.5 billion years ago some of these expan-
sions gave rise to endogenous compound metabolizing genes,
and the last xenobiotic metabolizing expansion occurred around
400 million years ago. CYPs are phylogenetically, one of the most
rapidly evolving genes, which is a characteristic that is needed to
protect the cells from injuries when exposed to increasing toxic
xenobiotic compounds. Genomic sequencing of cytochrome
P450 s (CYPs) found that there are around 57 functional genes
and 58 pseudogenes related to its synthesis in humans [11]. It
belongs to a multigene family and encodes proteins with amino
acid sequence identities >40%. Subfamilies include related proteins
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and 43 subfamilies in human CYPs. The families are named CYP1,
2, 3, 4, 5, 7, 8, 11, 17, 19, 20, 21, 24, 26, 27, 39, 46 and 51. Among
these families CYP2, 3 and 4 contain far more members than other
15 families. The biggest family in human CYP is CYP2 which
includes 13 subfamilies and 16 functional genes. CYP genes often
occur in clusters, with several related genes and pseudogenes.
Psuedogenes are imperfect copies of genes that won’t code for
any proteins due to added up mutations by evolution but are seen
near active genes. There are mainly 7 clusters related to CYPs;
CYP2ABFGST, CYP2D, CYP2J, CYP3A, CYP4ABXZ, and CYP4F.
CYP2ABFGST is one of the largest clusters and contains CYP2A6
and CYP2B6 genes. CYP2D cluster contains CYP2D6 gene [12].
Cytochrome families contain clans like the mitochondrial clan (first
clan) that includes all the CYPs in the mitochondrial membrane.
Others are 2, 3, 4, 7, 19, 20, 26, 46 and 51. Evolutionary evidence
groups the families into clans; families within a single clan have
likely diverged from a common ancestor gene. Functionally CYPs
families are divided into two types; detoxification type (D type)
and biosynthesis type (B type). Out of 57 genes, 35 are D-type
genes, and 22 are B type genes. CYPs 1, 2, 3 and 4 are detoxification
type CYPs. B-type genes are more conserved than D-type genes as
proved by their psuedogenization rates; 0.2 vs. 6.9 per 100 million
years, .i.e. disappearance of B type genes is around 30 times less
than that of D type genes by mutation [13].
Human CYP2D6 gene belongs to chromosome 22q13.1 and con-
tains 12 exons. It is highly polymorphic. To date, more than 100
allelic variants and many sub-variants of the CYP2D6 gene have
been reported. As a part of the evolution of our intellectual capabil-
ity, we take restricted food items that have resulted in the loss of a
selection pressure to keep genes active. Thus human beings carry
only one functional CYP2D6 gene whereas rat harbours 6 and
mouse have nine functional genes. Evolution of human CYP2D
locus has involved removal of three genes, inactivation of two
(CYP2D7P and 8P) and partial inactivation of one. It includes fully
functional alleles, alleles with reduced function and null alleles.
Phenotypically they are divided as Ultrarapid Metabolizers
(UMs), Extensive Metabolizers (EM), Intermediate Metabolizers
(IM), and Poor Metabolizers (PM) based on comparing the meta-
bolic enzyme ratio of substrate drugs and composes approximately
3–5%, 70–80%, 10–17% and 5–10% of Caucasians respectively [14].
The final phenotypic activity depends on the highest functioning
allele; a person having EM allele and PM allele expresses EM phe-
notype. PMs having two non-functional alleles are seen in 19% of
African Americans, 1% Chinese population and 0.6% of South Indian
population [15]. They are at increased risk of adverse effects due to
increased plasma level of the parent drug. UM, phenotype due to
an additional functional gene is seen in 2% of Swedish Caucasians
and 16% of black Ethiopians. IMs have two reduced functional or
one reduced functional and non-functional allele. There is wide
variability in allele distribution among different ethnic groups
resulting in a variable percentage of metabolizers. PMs are mainly
found in Europe, UMs are present in North Africa and Oceania, IMs
are primarily located in Asia. There are around 109 different
CYP2D6 variant alleles (1⁄B through ⁄109), and around 507 SNPs
of which 10% are nonsynonymous, that affects the protein struc-
ture. These variants result from point mutations, deletions or addi-
tions, gene rearrangements and duplication of the entire gene. ⁄1A
refers to the wild type or reference type haplotype.5. Substrates of CYP2D6
CYP stands for cytochrome P450 superfamily, 2 is the family, 2D
is the subfamily, and 6 is the member number. It is represented in
other ways like – CYD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2,CYP2DL1, CYP11D6, P450C2D, P450DB1, CYP2D8P2, and P450-DB1.
Other names for this enzyme are microsomal monooxygenase,
xenobiotic monooxygenase, debrisoquine 4-hydroxylase. P450
can metabolize a large number of structurally diverse endogenous
and exogenous compounds due to a broad substrate specificity and
generally with a wide regio- and stereoselectivity. Substrates of
CYP2D6 are usually lipophilic bases with a planar hydrophobic aro-
matic ring and a nitrogen atom that can be protonated at physio-
logical pH and have a negative molecular electrostatic potential
above the planar part of the molecule. The nitrogen atom is consid-
ered to be essential for electrostatic interactions with the carboxy-
late group of amino acids in the active site of CYP2D6. The
prototypical substrates of CYP2D6 are debrisoquine and sparteine
which are widely used to determine the phenotype of CYP2D6-
mediated metabolism. Six SRS (Substrate Recognition Sites) are
present in P450 which displays distinct differences in their
substrate-binding residues. Molecular dynamics (MD) which com-
bines statistical mechanics, classical mechanics, and intermolecu-
lar potential solves equations of actions for particles and can find
the time-dependent atomic motions in CYP2D6 molecule following
substrate binding. Propranolol is a lipophilic base with aromatic
ring and nitrogen. Its interaction with cyp2d6 has been studied
extensively. At first nanosecond following binding of propranolol
Gly-218, Asp-301, Leu372, and Val374 change their location about
propranolol by more than 2A which is shown by MD simulation
[16]. The substrate binding cavity reorganizes by moving Glyc-
218 and Leu-372 closer towards propranolol and Val374moves
away from the substrate. Many of the TCAs, SSRIs, antipsychotics,
hypnotics, opioids, antiemetics, antimigraine, anti-parkinsonism,
antiarrhythmics, and beta blockers fits into the group of a substrate
of CYP2D6.6. Inhibitors of CYP2D6
CYP2D6 though is mostly non-inducible, is subjected to inhibi-
tion by many drugs and compounds that lead to drug-drug interac-
tions. Strobl et al. in 1993 used a compound ajmalicine which is a
potent inhibitor of CYP2D6 to find the structure- activity relation-
ship of inhibitor group and found that a tertiary nitrogen atom
which is protonated to higher degree at physiological pH and a flat
hydrophobic region, with plane perpendicular to N–H axis and
maximally extends up to a distance of 7.5A from the nitrogen atom
is seen in inhibitors [17]. Elongation of alkyl chain dramatically
increases the affinity of the compounds towards CYP2D6. The
drug-drug interaction can be minor, mild or fatal. For example,
CYP2D6 mediated venlafaxine-propafenone interaction may cause
hallucinations and psychomotor agitation. Quinidine inhibits
CYP2D6 mediated metabolic conversion of dextromethorphan
thereby increase systemic bioavailability and less ADRs when used
for pseudobulbar effect. The inhibitors can be irreversible inhibi-
tors or reversible inhibitors. The irreversible inhibitors are cime-
tidine, paroxetine, pimozide, methamphetamine,
metoclopramide, and desethylamiodarone. Some substrates and
other compounds are found to inhibit CYP2D6 reversibly. Antipsy-
chotics like olanzapine, chlorpromazine, fluphenazine, haloperidol,
thioridazine, risperidone, clozapine, trifluperidol are metabolized
by CYP2D6 and also significantly inhibit these enzymes. When
co-administered with antidepressants like amitriptyline, imipra-
mine, and fluoxetine, their plasma concentration will increase.
H1 receptor antagonists like terfenadine, antifungal agents like ter-
binafine are CYP2D6 inhibitors. Usage of nortriptyline with terbi-
nafine cause supratherapeutic drug levels in patients. Many
protease inhibitors like ritonavir are potent inhibitors, and coad-
ministration of ritonavir reduces the clearance of desipramine by
59%. Steroids like progesterone, testosterone are inhibitors and
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Lansoprazole, a potent inhibitor reduce the conversion of dex-
tromethorphan to dextrophan. CYP2D6 metabolizes amphetamine
analogs and they inhibit its action which can cause accumulation
of drugs and toxicity. Many natural products like Panax ginseng,
Ginkgo biloba inhibits CYP2D6 mediated debrisoquine metabo-
lism.[18]Table 1




























Functional classification of alleles of CYP2D6.
Null alleles *3 *4 *5 *6 *7 *8 *11 *12 *13 *14 *15 *16 *18 *19 *20
*21 *38 *40 *42 *44 *56 *62 *68 *92 *10 *101
Alleles with partial
function
*10 *14 *17 *18 *36 *41 *47 *49 *50 *51 *52 *54
*55 *57 *59 *69 *72
Alleles with largely normal
or increased activity
*2A *17  2 *27 *35 *39 *41  2 *48
Table 3
List of approved drugs that includes CYP2D6 information in drug label.























propranolol, ranolazine, ritonavir, timolol,
vortioxetine, dextromethorphan, quinidine,
aripiprazole










Atomoxetine, tolterodine7. Regulators of CYP2D6
Cytochrome functions are regulated by internal and external
factors at transcriptional, post-transcriptional, post-translational
and epigenetic levels. CYP3A4 activity is higher in females, but
clinical data on gender effects are conflicting in the case of CYP2D6
[19]. In general gender as a single factor only has a minor to mod-
erate effect on CYP2D6 activity in humans. There is a positive cor-
relation between postnatal age and increasing CYP2D6 activity; a
gradual increase over the first year of life such that adult enzyme
levels would not be achieved until approximately six months of
age. Some studies have shown that there is a remarkably lower
activity in >7 days to 18 years compared to adult value but could
not find a convincing explanation for this. Mouse studies have
found that activity and expression of the enzyme increases during
pregnancy. Pregnancy is known to induce CYP2D6 mediated drug
metabolism in women. For example plasma clearance of metopro-
lol increased 2–13 folds during pregnancy as compared to that
after delivery [20]. Though drinking and smoking alter the activity
of many CYPs, it is less significant in the case of 2D6 except regard-
ing extensive metabolizers where it is slightly more. Alcoholic cir-
rhosis mainly affects the expression of drug transporters like SLCO
but a minor impact on CYPs. Herbal medicines like Panax ginseng
inhibits 2D6 activity by around 7% whereas goldenseal inhibits its
activity by around 50% and thus has a potential for clinical interac-
tions with drugs that are CYP substrates [21].
The human CYP2D6 enzyme is mainly uninducible by prototyp-
ical inducers like rifampicin, phenobarbital during in vitro studies
whereas some in vivo studies have shown conflicting results. SHP
(Small Heterodimer Partner), an orphan nuclear receptor can regu-
late the expression of CYP2D6 by inhibition. Another nuclear
receptor HNF-4alpha (Hepatocyte Nuclear Factor) governs the
transcription of CYP2D6, so that suppression of HNF 4 alpha causes
decreases in mRNA levels of CYP2D6 [22]. Thus genetic variation in
HNF can affect CYP levels. Liver specimens with heterozygous HNF-
4alpha Gly60Asp genotype tend to have lower levels of CYP2D6
compared to wild type. NO (Nitric Oxide) through its effect on
HNF-4alpha down regulate the transcription of 2D6. FXRs (Farne-
soid X receptor) are nuclear hormone receptors which participate
in bilirubin metabolism in liver, intestine, and kidney. FXR agonists
like obeticholic acids decrease hepatic cyp2d6 expression suggest-
ing the potential drug-drug interaction between CYP2D6 sub-
strates and FXR agonists [22]. CYP2D6 is post-translationally
modified by phosphorylation, but data regarding its regulation is
limited. Genome-wide association studies (GWA) have shown that
some SNPs like CYP2D6⁄4, ⁄10 and ⁄14 are associated with reduced
activity of the enzyme. Of the 54 SNPs associated with CYP enzyme
activities, 30 are related to CYP2D6 activity, and they are all located
within 200 kb distance of the physical location of the CYP2D6 gene
[23]. Diseases like liver disease, renal disease, rheumatoid arthritis
and other inflammatory diseases have some effects on CYP activity.
The liver disease reduces the activity of CYPs but has less effect on
CYP2D6. Covalent binding of toxic metabolites to CYP leads to the
formation of anti-CYP antibodies and immune-mediated hepato-
toxicity. Liver Kidney Microsomal type1 antibodies (LKM-1) target-
ing CYP2D6 in hepatocytes are detected in the plasma of patients
with chronic hepatitis C. Autoimmune hepatitis type B I character-ized to be mainly related to drug-metabolizing enzymes as auto
antigens, such as LKM-1 against CYP2D6.Antibodies might bring
about a targeted functional inhibition via ligand like interaction
at the level of the CYP2D6 cavity, corresponding to the dominant
immune epitope. Further studies are needed to clarify the role of
nuclear, epigenetic and other factors in the regulation of CYP2D6
as it seems to be less affected than other CYPs.
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In the 1970s and 80s, debrisoquine hydroxylation and exagger-
ated hypotensive effects from that drug were related to an autoso-
mal recessive inherited deficiency in CYP2D6. Mahgoub et al. and
Eichelbaum et al. have discovered that metabolism of debrisoquine
and sparteine is polymorphic which was later shown to be due to
CYP2D6 polymorphisms [24]. CYP2D6 can metabolize more than
160 drugs and cause significant effect on response and clearance
of its substrate drugs. Several guidelines have come so as to max-
imise therapeutic effect and minimize toxicity. CPIC (Clinical Phar-
macogenetics Implementation Consortium) guidelines are
available for ten drugs, and DPWG (Dutch Pharmacogenetics
Working Group) have put guidelines for 26 drugs see Table 1 [25].
Functionally alleles of CYP2D6 can be classified into three
groups; alleles with normal or increased activity and decreased
activity or loss of activity. See Table 2.
FDA (US Food and Drug Administration) has mentioned CYP2D6
effects in the drug labels of 48 drugs, EMA (European Medicine
Agency) has listed it in13 drugs, HCSC (Health Canada sante
Canada) in 16 drugs and PMDA (Pharmaceuticals and Medical
Device Agency) in 2 drugs. See Table 3.
9. Conclusions and future perspectives
CYP2D6 polymorphism affects the clinical outcome of pharma-
cotherapy due to resulting metabolizer status. If the parent drug is
active, then UMs may experience a lack of efficacy whereas PMs
will suffer toxicity. A number of allelic variants have been added
in the list which predicts the clinical success. Knowing more about
the variants adds our knowledge and helps to develop treatment
algorithms for many drugs. Given that genotyping test for CYP2D6
is not routinely performed in clinical practice, further prospective
studies on the clinical impact of CYP2D6- dependent metabolism
of drugs are warranted in large cohorts of samples.
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